Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
Rhea-AI Summary
Zymeworks (Nasdaq: ZYME) will report fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Management will host a conference call and webcast the same day at 8:30 am Eastern Time to discuss results and provide a corporate update.
Positive
- None.
Negative
- None.
News Market Reaction – ZYME
In the Feb 12 session, ZYME gained 1.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Conference participation | Positive | +1.5% | Announced multiple investor conference appearances in Feb–Mar 2026. |
| Jan 12 | Leadership changes | Neutral | -0.0% | Board and executive role changes to support updated corporate strategy. |
| Jan 11 | Strategy & outlook | Positive | -0.0% | Outlined 2026 strategy, Phase 3 success, milestones up to $440.0M and cash of $270.6M. |
| Jan 06 | Phase 3 results | Positive | -5.1% | Reported strong HERIZON-GEA-01 survival and PFS benefits for Ziihera combinations. |
| Dec 02 | Conference schedule | Positive | +4.5% | Announced ASCO GI and J.P. Morgan conference participation and presentation timings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows positive clinical and strategic updates sometimes met with weak or negative price reactions, while conference participation headlines have drawn more supportive responses.
Over the past few months, Zymeworks has highlighted major clinical and strategic milestones, including strong Phase 3 HERIZON-GEA-01 data and eligibility for up to $440.0M in GEA regulatory milestones, plus cash and marketable securities of about $270.6M as of Dec 31, 2025. Investor events and conference participation on Dec 2, 2025 and Jan 27, 2026 saw positive price reactions. By contrast, detailed strategic and clinical updates in early January sometimes coincided with flat to negative moves, underscoring uneven sentiment heading into the upcoming earnings call.
Key Terms
biotherapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 2, 2026 at 8:30 am Eastern Time (ET).
About Zymeworks Inc.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Investor inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com
